Adalvo is pleased to announce the successful DCP submission for Brivaracetam Film-Coated Tablets on Day 1 after the expiry of the Data Exclusivity period, developed in collaboration with one of our strategic partners.
Brivaracetam Film Coated Tablets has been developed based on the reference brand Briviact. The product is indicated as an adjunctive therapy in the treatment of partial-onset seizures.
The brand sold approximately $635 Mn globally in 2022, having a significant growth potential with a Global 3Y CAGR of 17%, according to IQVIA.
With our clearly defined product pathway, we believe we can achieve a day-1 launch in all major markets.
Adalvo's commitment to advancing neurological therapies goes beyond this successful submission. Our CNS portfolio includes, but is not limited to;
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!